Cargando…

TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis

Thyroid hormone receptor interactor 13 (TRIP13) plays a crucial role in poor prognosis and chemotherapy resistance of cancer patients. This present study is aimed at investigating the role of high expression of TRIP13 inducing nedaplatin (NDP) resistance in esophageal squamous cell carcinoma (ESCC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lin-Ting, Ke, Li-Xin, Wu, Xin-Yi, Tian, Hui-Ting, Deng, Hua-Zhen, Xu, Li-Yan, Li, En-Min, Long, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115607/ https://www.ncbi.nlm.nih.gov/pubmed/35601150 http://dx.doi.org/10.1155/2022/7295458

Ejemplares similares

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma
por: Zhu, Huiping, et al.
Publicado: (2022)

Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2009)

Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: A retrospective study
por: Watanabe, Akinori, et al.
Publicado: (2018)

Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma
por: Huo, Rui-Xue, et al.
Publicado: (2022)

DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity
por: Hama, Taketsugu, et al.
Publicado: (2021)

Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
por: Osawa, Satoshi, et al.
Publicado: (2009)

Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma
por: Yajima, Satoshi, et al.
Publicado: (2021)

Phase I trial of nedaplatin and S-1 in patients with advanced squamous cell lung cancer
por: Kanaji, Nobuhiro, et al.
Publicado: (2020)

Mouse Pachytene Checkpoint 2 (Trip13) Is Required for Completing Meiotic Recombination but Not Synapsis
por: Li, Xin, et al.
Publicado: (2007)

Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study
por: Chen, Jiakuan, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study
por: Ohnuma, Hiroyuki, et al.
Publicado: (2018)

Correction: Mouse Pachytene Checkpoint 2 (Trip13) Is Required for Completing Meiotic Recombination but Not Synapsis
por: Chenglin Li, Xin, et al.
Publicado: (2007)

Comparison of efficacy and toxicity between nedaplatin and cisplatin in treating malignant pleural effusion
por: Zhong, Li-Zhe, et al.
Publicado: (2018)

HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair
por: Zhou, Ting, et al.
Publicado: (2019)

Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers
por: Tian, Yijun, et al.
Publicado: (2017)

A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix
por: Yuan, Guangwen, et al.
Publicado: (2014)

Disassembly of the Shieldin Complex by TRIP13
por: Sarangi, Prabha, et al.
Publicado: (2020)

Nedaplatin: a cisplatin derivative in cancer chemotherapy
por: Shimada, Muneaki, et al.
Publicado: (2013)

Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report
por: ZHAN, PING, et al.
Publicado: (2015)

Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells
por: Liu, Zhongyu, et al.
Publicado: (2015)

Nedaplatin-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report and review of the literature
por: Tian, Lei, et al.
Publicado: (2021)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Interleukin 13 participates in terminal differentiation of esophageal squamous cell carcinoma cells
por: Li, Jian, et al.
Publicado: (2022)

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
por: Ueda, Hiroto, et al.
Publicado: (2018)

Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma
por: Xu, Hongyan, et al.
Publicado: (2022)

MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair
por: de Krijger, Inge, et al.
Publicado: (2021)

High Expression of GOLPH3 in Esophageal Squamous Cell Carcinoma Correlates with Poor Prognosis
por: Wang, Jian-Hua, et al.
Publicado: (2012)

Comparative Nephrotoxicity of Cisplatin and Nedaplatin: Mechanisms and Histopathological Characteristics
por: Uehara, Takeki, et al.
Publicado: (2011)

Nedaplatin: A Radiosensitizing Agent for Patients with Cervical Cancer
por: Mabuchi, Seiji, et al.
Publicado: (2011)

TRIP13-deficient tubular epithelial cells are susceptible to apoptosis following acute kidney injury
por: Pressly, Jeffrey D., et al.
Publicado: (2017)

Arenobufagin activates p53 to trigger esophageal squamous cell carcinoma cell apoptosis in vitro and in vivo
por: Lv, Junhong, et al.
Publicado: (2017)

TRIP 13-dependent pathways promote the development of gastric cancer
por: Ni, Fengming, et al.
Publicado: (2023)

Trip and Trip Pro
por: Fox, Lynne M.
Publicado: (2018)

Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer
por: Jingu, Keiichi, et al.
Publicado: (2006)

Bufadienolides induce p53-mediated apoptosis in esophageal squamous cell carcinoma cells in vitro and in vivo
por: Lin, Shaohuan, et al.
Publicado: (2018)

Clinical Significance and Systematic Expression Analysis of the Thyroid Receptor Interacting Protein 13 (TRIP13) as Human Gliomas Biomarker
por: Chen, Ssu-Han, et al.
Publicado: (2021)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_80elkbf24ie15a1o2ic6fgsh68